Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity (2016 - 2025)

Historic Common Equity for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $126.6 million.

  • Enanta Pharmaceuticals' Common Equity rose 1321.37% to $126.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $126.6 million, marking a year-over-year increase of 1321.37%. This contributed to the annual value of $64.7 million for FY2025, which is 4975.93% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Common Equity of $126.6 million as of Q4 2025, which was up 1321.37% from $64.7 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Common Equity's 5-year high stood at $436.0 million during Q1 2021, with a 5-year trough of $64.7 million in Q3 2025.
  • For the 5-year period, Enanta Pharmaceuticals' Common Equity averaged around $239.6 million, with its median value being $227.3 million (2023).
  • Data for Enanta Pharmaceuticals' Common Equity shows a peak YoY increase of 1321.37% (in 2025) and a maximum YoY decrease of 4975.93% (in 2025) over the last 5 years.
  • Enanta Pharmaceuticals' Common Equity (Quarter) stood at $384.4 million in 2021, then dropped by 21.74% to $300.8 million in 2022, then crashed by 36.22% to $191.9 million in 2023, then crashed by 41.73% to $111.8 million in 2024, then increased by 13.21% to $126.6 million in 2025.
  • Its Common Equity was $126.6 million in Q4 2025, compared to $64.7 million in Q3 2025 and $79.3 million in Q2 2025.